Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Sean Maduck Biography and Net Worth

Insider of Corcept Therapeutics

Mr. Maduck was named Corcept’s Chief Commercial Officer in 2020. Prior to that he was Corcept’s Senior Vice President, Commercial. Before that, he was the company’s Vice President, Sales & Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an AB from Dartmouth College, a BE in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College and a Masters in Management from the Stanford Graduate School of Business.

What is Sean Maduck's net worth?: The estimated net worth of Sean Maduck is at least $4.78 million as of May 13th, 2024. Mr. Maduck owns 85,222 shares of Corcept Therapeutics stock worth more than $4,780,102 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Maduck may own. Additionally, Mr. Maduck receives an annual salary of $1,050,000.00 as Insider at Corcept Therapeutics. Learn More about Sean Maduck's net worth.
How old is Sean Maduck?: Mr. Maduck is currently 47 years old. There are 6 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Sean Maduck's age.
What is Sean Maduck's salary?: As the Insider of Corcept Therapeutics Incorporated, Mr. Maduck earns $1,050,000.00 per year. There are 2 executives that earn more than Mr. Maduck. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who commands a salary of $2,430,000.00 per year. Learn More on Sean Maduck's salary.
How do I contact Sean Maduck?: The corporate mailing address for Mr. Maduck and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Sean Maduck's contact information.
Has Sean Maduck been buying or selling shares of Corcept Therapeutics?: Sean Maduck has not been actively trading shares of Corcept Therapeutics in the last ninety days. Most recently, Sean Maduck sold 50,000 shares of the business's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $28.00, for a transaction totalling $1,400,000.00. Following the completion of the sale, the insider now directly owns 85,222 shares of the company's stock, valued at $2,386,216. Learn More on Sean Maduck's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 11/11/2024.

Sean Maduck Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/13/2024	Sell	50,000	$28.00	$1,400,000.00	85,222
3/27/2024	Sell	25,953	$25.01	$649,084.53	85,222
3/18/2024	Sell	17,219	$25.00	$430,475.00	75,222
2/16/2024	Sell	27,068	$25.97	$702,955.96	74,455
12/1/2023	Sell	25,000	$25.56	$639,000.00	73,291
11/1/2023	Sell	5,112	$28.08	$143,544.96	73,291
10/10/2023	Sell	18,471	$27.29	$504,073.59	73,291
10/6/2023	Sell	3,498	$27.24	$95,285.52	73,610
10/2/2023	Sell	3,031	$27.24	$82,564.44	73,610
9/19/2023	Sell	25,000	$32.48	$812,000.00	73,610
12/1/2022	Sell	625	$25.28	$15,800.00	56,462
11/10/2022	Sell	25,000	$25.57	$639,250.00	56,462
10/3/2022	Sell	25,000	$25.64	$641,000.00	56,462
8/9/2022	Sell	200	$28.70	$5,740.00	40,024
7/18/2022	Sell	25,000	$27.37	$684,250.00	40,024
10/5/2021	Sell	637	$20.00	$12,740.00
10/1/2021	Sell	24,363	$20.00	$487,260.00
9/1/2021	Sell	25,000	$21.40	$535,000.00	65,024
8/3/2021	Sell	25,000	$21.18	$529,500.00	65,024
7/7/2021	Sell	25,000	$22.19	$554,750.00
2/16/2021	Sell	8,989	$28.25	$253,939.25	33,424
2/11/2021	Sell	3,400	$29.78	$101,252.00	33,424
12/12/2018	Sell	60,000	$19.01	$1,140,600.00	65,015

Sean Maduck Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $56.09

$54.02

$56.13

50 Day Range

MA: $47.62

$35.71

$59.60

2 Week Range

Now: $56.09

$20.84

$61.66

Volume

1,013,492 shs

Average Volume

1,182,597 shs

Market Capitalization

$5.88 billion

P/E Ratio

44.52

Dividend Yield

N/A

Beta

0.45

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide

Sean Maduck Biography and Net Worth

What is Sean Maduck's net worth?

How old is Sean Maduck?

What is Sean Maduck's salary?

How do I contact Sean Maduck?

Has Sean Maduck been buying or selling shares of Corcept Therapeutics?

Who are Corcept Therapeutics' active insiders?

Are insiders buying or selling shares of Corcept Therapeutics?